Pembrolizumab in advanced renal cell carcinoma: a meta-analysis providing level 1a evidence

The recent introduction of immunotherapy in the first line setting of advanced renal cell carcinoma (aRCC) has dramatically improved patients’ prognosis. The aim of the current meta-analysis was to provide level 1a evidence supporting the use of pembrolizumab plus tyrosine kinase inhibitors (TKI) as...

Full description

Bibliographic Details

Published in:	Current problems in cancer Vol. 46; no. 4; p. 100875
Main Authors:	Capitanio, Umberto, Fallara, Giuseppe, Raggi, Daniele, Nocera, Luigi, Larcher, Alessandro, Belladelli, Federico, Rowe, Isaline, Briganti, Alberto, Salonia, Andrea, Karakiewicz, Pierre, Montorsi, Francesco, Martini, Alberto, Necchi, Andrea
Format:	Journal Article
Language:	English
Published:	United States Elsevier Inc 01-08-2022
Subjects:	Advanced RCC, Pembrolizumab, Immunotherapy, Overall survival, Progression free survival mRCC mRCC Advanced RCC, Pembrolizumab, Immunotherapy, Overall survival, Progression free survival
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!